Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Feb 1, 2025 | (Q4)Feb 1, 2025 | (Q3)Nov 2, 2024 | (Q2)Aug 3, 2024 | (Q1)May 4, 2024 | (FY)Feb 3, 2024 | (Q4)Feb 3, 2024 | (Q3)Oct 28, 2023 | (Q2)Jul 29, 2023 | (Q1)Apr 29, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -2.20%7.99B | -5.70%2.25B | -1.41%1.96B | 1.93%1.9B | -2.69%1.88B | -6.75%8.17B | 2.01%2.38B | -8.59%1.99B | -9.86%1.86B | -11.34%1.93B |
Operating revenue | -2.20%7.99B | -5.70%2.25B | -1.41%1.96B | 1.93%1.9B | -2.69%1.88B | -6.75%8.17B | 2.01%2.38B | -8.59%1.99B | -9.86%1.86B | -11.34%1.93B |
Cost of revenue | -3.88%5.67B | -9.51%1.58B | -4.50%1.38B | 1.18%1.37B | -1.04%1.34B | -1.01%5.9B | 6.99%1.75B | -2.30%1.44B | -3.83%1.36B | -5.99%1.35B |
Gross profit | 2.16%2.32B | 4.70%668M | 6.78%583M | 3.94%527M | -6.53%544M | -18.94%2.27B | -9.50%638M | -21.89%546M | -22.83%507M | -21.67%582M |
Operating expense | 3.46%2.12B | -5.82%550M | 8.11%533M | 7.11%527M | 6.22%512M | -2.84%2.05B | 2.10%584M | -5.01%493M | -2.19%492M | -6.77%482M |
Selling and administrative expenses | 3.67%1.92B | -6.00%501M | 8.07%482M | 7.69%476M | 6.96%461M | -2.68%1.85B | 2.30%533M | -4.50%446M | -2.21%442M | -6.91%431M |
-General and administrative expense | 3.67%1.92B | ---- | ---- | ---- | 6.96%461M | -2.68%1.85B | ---- | ---- | ---- | -6.91%431M |
Depreciation amortization depletion | 1.51%202M | -3.92%49M | 8.51%51M | 2.00%51M | 0.00%51M | -4.33%199M | 0.00%51M | -9.62%47M | -1.96%50M | -5.56%51M |
-Depreciation and amortization | 1.51%202M | -3.92%49M | 8.51%51M | 2.00%51M | 0.00%51M | -4.33%199M | 0.00%51M | -9.62%47M | -1.96%50M | -5.56%51M |
Operating profit | -9.91%200M | 118.52%118M | -5.66%50M | 0 | -68.00%32M | -67.97%222M | -59.40%54M | -70.56%53M | -90.26%15M | -55.75%100M |
Net non-operating interest income expense | 11.11%-8M | 0.00%-2M | 0.00%-2M | 25.00%-3M | 0.00%-1M | 40.00%-9M | 0.00%-2M | 33.33%-2M | 20.00%-4M | 80.00%-1M |
Non-operating interest expense | -11.11%8M | 0.00%2M | 0.00%2M | -25.00%3M | 0.00%1M | -40.00%9M | 0.00%2M | -33.33%2M | -20.00%4M | -80.00%1M |
Other net income (expense) | 77.83%-141M | 93.23%-39M | -1,725.00%-73M | 21.43%-11M | 57.14%-18M | -312.99%-636M | -593.98%-576M | 88.24%-4M | -133.33%-14M | -35.48%-42M |
Gain on sale of security | ---- | ---- | ---35M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Earnings from equity interest | -100.00%-2M | --0 | --0 | --0 | -100.00%-2M | -200.00%-1M | --0 | --0 | --0 | ---1M |
Special income (charges) | 74.86%-132M | 85.80%-71M | ---38M | -80.00%-9M | 30.00%-14M | -368.75%-525M | -316.67%-500M | --0 | -350.00%-5M | 35.48%-20M |
-Less:Restructuring and merger&acquisition | 100.00%26M | 1,800.00%19M | 0.00%7M | --0 | --0 | 360.00%13M | 109.09%1M | 133.33%7M | 200.00%3M | 0.00%2M |
-Less:Impairment of capital assets | 46.15%57M | -50.00%10M | 1,650.00%31M | 200.00%9M | -61.11%7M | -40.91%39M | -67.21%20M | ---2M | 50.00%3M | 500.00%18M |
-Less:Other special charges | 1,300.00%14M | --7M | ---- | ---- | --7M | -88.89%1M | ---- | ---- | ---- | ---- |
-Write off | -92.68%35M | -92.66%35M | --0 | --0 | ---- | 683.61%478M | 681.97%477M | --0 | -92.31%1M | ---- |
-Gain on sale of business | --0 | --0 | --0 | --0 | ---- | -84.21%3M | ---1M | 100.00%2M | -88.89%2M | ---- |
-Gain on sale of property,plant,equipment | --0 | --0 | --0 | ---- | ---- | --3M | --0 | --3M | ---- | ---- |
Other non- operating income (expenses) | 93.64%-7M | 96.05%-3M | ---- | 77.78%-2M | 90.48%-2M | -155.81%-110M | -406.67%-76M | 76.47%-4M | 0.00%-9M | ---21M |
Income before tax | 112.06%51M | 114.69%77M | -153.19%-25M | -366.67%-14M | -77.19%13M | -180.73%-423M | -1,191.67%-524M | -67.13%47M | -102.10%-3M | -70.00%57M |
Income tax | 135.48%33M | 116.30%22M | -57.89%8M | -200.00%-2M | -76.19%5M | -151.67%-93M | -619.23%-135M | -59.57%19M | -95.92%2M | -63.79%21M |
Net income | 103.64%12M | 112.60%49M | -217.86%-33M | -140.00%-12M | -77.78%8M | -196.77%-330M | -2,147.37%-389M | -70.83%28M | -105.32%-5M | -72.73%36M |
Net income continuous Operations | 105.45%18M | 114.14%55M | -217.86%-33M | -140.00%-12M | -77.78%8M | -195.93%-330M | -1,868.18%-389M | -70.83%28M | -105.32%-5M | -72.73%36M |
Net income discontinuous operations | ---6M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Minority interest income | 0 | 0 | ||||||||
Net income attributable to the parent company | 103.64%12M | 112.60%49M | -217.86%-33M | -140.00%-12M | -77.78%8M | -196.49%-330M | -2,147.37%-389M | -70.83%28M | -105.32%-5M | -72.93%36M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 103.64%12M | 112.60%49M | -217.86%-33M | -140.00%-12M | -77.78%8M | -196.49%-330M | -2,147.37%-389M | -70.83%28M | -105.32%-5M | -72.93%36M |
Basic earnings per share | 103.70%0.13 | 112.47%0.5164 | -213.33%-0.34 | -160.00%-0.13 | -76.92%0.09 | -196.96%-3.51 | -2,170.00%-4.14 | -70.59%0.3 | -105.00%-0.05 | -71.74%0.39 |
Diluted earnings per share | 103.70%0.13 | 112.32%0.51 | -213.33%-0.34 | -160.00%-0.13 | -76.32%0.09 | -198.04%-3.51 | -2,170.00%-4.14 | -70.30%0.3 | -105.05%-0.05 | -72.26%0.38 |
Dividend per share | 0 | 0 | 0 | 0 | 0 | -25.00%1.2 | 0 | 0.00%0.4 | 0.00%0.4 | 0.00%0.4 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |